Calculus News and Research

RSS

MIP Discovery Closes £7M Series a Financing to Drive Commercialization in Cell and Gene Therapy Space

MIP Discovery, an innovative developer of non-biological affinity reagents designed to accelerate the development and production of cell and gene therapies, today announced it has closed a £7 million GBP (~$9 million USD) Series A financing round, led by Mercia Ventures.

21 Feb 2024

Protein Analysis of Ancient Cauldrons Reveals Diet of Caucasus People

Archaeologists have long been drawing conclusions about how ancient tools were used by the people who crafted them based on written records and context clues.

21 Aug 2023

MIP Diagnostics secures £7.3M investment following achievement of critical milestones

Mercia Asset Management, Calculus Capital, Downing Ventures and BGF scale joint investment in latest fundraise.

From MIP Discovery 1 Mar 2022

Study traces antibiotic impact by analyzing the oral microbiome of bears

Historical museum collections were used by scientists to analyze the impacts of human-made antibiotics over the complete history of their application.

31 Aug 2021

High levels of antibiotic resistance in wild Swedish bears follow human antibiotic use

An international team of researchers used historical museum collections to study the effects of human-made antibiotics over the entire history of their application.

27 Aug 2021

Scientists identify the language the body uses to marshal responses to threats

UCLA life scientists have identified six "words" that specific immune cells use to call up immune defense genes -- an important step toward understanding the language the body uses to marshal responses to threats.

13 May 2021